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Abstract
Background: Adrenomedullin (ADM) regulates vascular tone and endothelial permeability during sepsis. Levels
of circulating biologically active ADM (bio-ADM) show an inverse relationship with blood pressure and a
direct relationship with vasopressor requirement. In the present prospective observational multinational
Adrenomedullin and Outcome in Sepsis and Septic Shock 1 (, AdrenOSS-1) study, we assessed relationships
between circulating bio-ADM during the initial intensive care unit (ICU) stay and short-term outcome in order
to eventually design a biomarker-guided randomized controlled trial.
Methods: AdrenOSS-1 was a prospective observational multinational study. The primary outcome was 28-day
mortality. Secondary outcomes included organ failure as defined by Sequential Organ Failure Assessment
(SOFA) score, organ support with focus on vasopressor/inotropic use, and need for renal replacement therapy.
AdrenOSS-1 included 583 patients admitted to the ICU with sepsis or septic shock.
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Results: Circulating bio-ADM levels were measured upon admission and at day 2. Median bio-ADM
concentration upon admission was 80.5 pg/ml [IQR 41.5–148.1 pg/ml]. Initial SOFA score was 7 [IQR 5–10],
and 28-day mortality was 22%. We found marked associations between bio-ADM upon admission and 28-day
mortality (unadjusted standardized HR 2.3 [CI 1.9–2.9]; adjusted HR 1.6 [CI 1.1–2.5]) and between bio-ADM
levels and SOFA score (p < 0.0001). Need of vasopressor/inotrope, renal replacement therapy, and positive
fluid balance were more prevalent in patients with a bio-ADM > 70 pg/ml upon admission than in those
with bio-ADM ≤ 70 pg/ml. In patients with bio-ADM > 70 pg/ml upon admission, decrease in bio-ADM
below 70 pg/ml at day 2 was associated with recovery of organ function at day 7 and better 28-day
outcome (9.5% mortality). By contrast, persistently elevated bio-ADM at day 2 was associated with prolonged
organ dysfunction and high 28-day mortality (38.1% mortality, HR 4.9, 95% CI 2.5–9.8).
Conclusions: AdrenOSS-1 shows that early levels and rapid changes in bio-ADM estimate short-term outcome in
sepsis and septic shock. These data are the backbone of the design of the biomarker-guided AdrenOSS-2 trial.
Trial registration: ClinicalTrials.gov, NCT02393781. Registered on March 19, 2015.
Keywords: Biomarker, Outcome, Sepsis-2, Sepsis-3
Introduction
Adrenomedullin (ADM) is a free circulating peptide with
potent vascular properties, including benefits for endothe-
lial barriers at physiological levels. ADM has previously
been described as a “double-edged sword” in sepsis [1]
because high levels of ADM induce vasodilation and
hypotension [2–4] on one hand while reinforcing the
endothelial barrier and improving outcome on the other
[5–10]. The potential of ADM as a prognostic biomarker
has previously been studied in critically ill patients, often
by measuring the inactive midregional pro-ADM [11, 12],
or recently by direct measurement of the bioactive form
of ADM (bio-ADM) [13, 14]. It has been shown repeat-
edly that bio-ADM greater than 70 pg/ml is associated
with worse outcome [13, 14].
On the basis of previous results, we tested the hypoth-
esis that modulating the ADM pathway in patients with
high levels of circulating bio-ADM may improve short-
term outcome in sepsis. Adrecizumab, a monoclonal
anti-ADM antibody, has been shown to improve organ
function in preclinical settings [15]. In order to design a
human trial in which we would administer adrecizumab
based on levels of bio-ADM, we needed to assess the rela-
tionship between initial levels of bio-ADM and short-term
outcome in sepsis and in septic shock patients.
In the Adrenomedullin and Outcome in Sepsis and
Septic Shock 1 (AdrenOSS-1) study, we investigated
whether the initial plasma concentration of bio-ADM
(on intensive care unit [ICU] admission and after 48 h)
may provide insight into 28-day survival and the recov-
ery of organ function.
Methods
Study design
AdrenOSS-1 was a European prospective observational
study. Twenty-four centers in five countries (France,
Belgium, The Netherlands, Italy, and Germany) contrib-
uted to the trial achievement of 583 enrolled patients.
Patients were recruited from June 2015 to May 2016. The
study protocol was approved by the local ethics commit-
tees and was conducted in accordance with Directive
2001/20/EC, as well as good clinical practice (Inter-
national Conference on Harmonization Harmonized Tri-
partite Guideline version 4 of May 1, 1996, and decision
of November 24, 2006) and the Declaration of Helsinki.
The study enrolled patients aged 18 years and older
who were (1) admitted to the ICU for sepsis or septic
shock or (2) transferred from another ICU in the state
of sepsis and septic shock within less than 24 h after
admission. Included patients were stratified by severe
sepsis and septic shock based on definitions for sepsis
and organ failure from 2001 [16]. In the present article,
the term “sepsis” refers to the updated definition of
Sepsis-3 [17]. Concerning septic shock, most data pre-
sented in this article are based on the former definition
[16], except for the confirmatory analyses presented in
the last paragraph of the “Results” section, for which the
new Sepsis-3 definition of septic shock was used [17].
Exclusion criteria were pregnancy, vegetative coma, and
participation in an interventional trial in the preceding
month. Informed consent was obtained from all patients
or their lawful representatives prior to enrollment in the
study. Patients were treated according to local practice,
and treatments as well as procedures were registered.
The primary endpoint was 28-day mortality. Secondary
endpoints concerned organ failure (as defined by the
Sequential Organ Failure Assessment [SOFA] score) and
organ support, vasopressor/inotrope use, fluid balance,
and use of renal replacement therapy (RRT), as well as val-
idation of the previously identified cutoff value of 70 pg/
ml [14]. The latter was identified as the optimal screening
cutoff for AdrenOSS-2, an ongoing proof-of-concept and
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dose-finding phase II trial assessing adrecizumab (an anti-
body modulating circulating bio-ADM) in patients with
early septic shock (NCT03085758). The relationship be-
tween cardiovascular SOFA subscore and bio-ADM, being
a biomarker of vascular dysfunction, was evaluated.
Collection of patient data
Upon admission, demographics (age, sex), body mass
index, presence of septic shock, type of ICU admission,
organ dysfunction scores (SOFA, Acute Physiologic As-
sessment and Chronic Health Evaluation II [APACHE II]),
origin of sepsis, preexisting comorbidities (i.e., treated
within the last year), past medical history, laboratory
values, and organ support were recorded, and blood was
drawn for measurement of bio-ADM and other markers.
After patient enrollment, the following data were col-
lected daily during the first week: SOFA score, anti-
microbial therapies, fluid balance, ventilation status,
Glasgow Coma Scale score, central venous pressure,
need for RRT, invasive procedures for sepsis control, and
vasopressor/inotrope treatment. Moreover, discharge
status and mortality were recorded on day 28 after ICU
admission.
Sample collection
Blood for the central laboratory was sampled within
24 h after ICU admission and on day 2 (mean 47 h, SD
9 h) after the first sample. Samples were subsequently
processed and stored at − 80 °C before transfer to the
central laboratory for blinded bio-ADM analysis organized
by the study sponsor (sphingotec GmbH, Hennigsdorf,
Germany). Routine analyses (e.g., partial pressure of
arterial oxygen, lactate) were performed by the local
laboratories.
Bio-ADM measurement
Bio-ADM was measured using a recently developed im-
munoassay provided by sphingotec GmbH. For details
and design principles on the assay, see publications by
Marino et al. [14] and Weber et al. [18]. The analytical
assay sensitivity was 2 pg/ml.
Statistical analyses
Results are presented as number and percentage, mean
and SD, or median and IQR, depending on their distri-
bution. Group comparisons for continuous variables
were performed using the Kruskal-Wallis test, and ap-
propriate post hoc tests were applied if necessary. Cat-
egorical data were compared using the chi-square test
with simulated p values using 2000 replicates. Biomarker
data were log-transformed if necessary. Cox proportional
hazards regression was used to analyze the effect of risk
factors on survival in uni- and multivariable analyses.
The assumptions of proportional hazards were tested for
all variables. For continuous variables, HRs were stan-
dardized to describe the HR for a biomarker change of
one IQR. CIs (95% CI) for risk factors and significance
levels for chi-square (Wald) test are given. The predict-
ive value of each model was assessed by the model likeli-
hood ratio chi-square statistic. The concordance index
(C index) is given as an effect measure. It is equivalent
to the concept of AUC adopted for binary outcome. For
multivariable models, a bootstrap-corrected version of
the C index is given. To test for added predictive value,
we used the likelihood ratio chi-square test for nested
models to assess whether bio-ADM adds predictive
value to a clinical model or a risk score. Survival curves
plotted by the Kaplan-Meier method using quartiles or
predefined cut points (70 pg/ml) of bio-ADM were used
for illustrative purposes. ROC curve analysis was applied
for 28-day mortality to determine the optimal Youden
cutoff in this cohort.
A two-sided p value of 0.05 was considered statistically
significant. All analyses were performed using R version
2.5.1 (http://www.r-project.org, library Design, Hmisc,
ROCR) and IBM SPSS Statistics version 22.0 software
(IBM, Armonk, NY, USA).
Results
A total of 583 patients were included in the AdrenOSS-1
study. Patient characteristics, organ dysfunction scores,
physiological and laboratory values, organ support upon
admission, and outcome parameters are presented in
Table 1. The median bio-ADM level at admission was
80.5 pg/ml [IQR 41.6–148.1] in our studied patients;
55.9% had bio-ADM level greater than 70 pg/ml at admis-
sion, and 44.1% had a bio-ADM less than 70 pg/ml. Of
note, patients with septic shock had a significantly higher
bio-ADM concentration at admission than patients with
sepsis (114.4 [62.6–214.5] versus 57.5 pg/ml [31.2–101.5],
p < 0.0001).
Bio-ADM levels and mortality
Over the 28-day follow-up period, 127 patients (22%)
died: 33 with sepsis and 94 with septic shock.
In a Cox proportional hazards model adjusted for age,
gender, comorbidities (cardiac and noncardiac), lactate,
and diagnosis (sepsis, septic shock), bio-ADM concen-
tration at admission was independently associated with
28-day mortality in the studied population (added
chi-square 12.2, p = 0.0005; adjusted standardized HR
1.6 [95% CI 1.1–2.5], p = 0.0004) (Table 2). Noticeably,
the C index for prediction of 28-day mortality for
bio-ADM at admission was 0.688 (95% CI 0.642–0.733,
chi-square 54.8, p < 0.0001) in the univariate Cox regres-
sion. C indexes for lactate, SOFA, and APACHE II were
0.720 (95% CI 0.672–0.768), 0.728 (95% CI 0.680–0.777),
and 0.701 (95% CI 0.657–0.746), respectively (all p <
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Table 1 Patient characteristics
Patient characteristics All Bio-ADM< 70 pg/ml
at admission
Bio-ADM> 70 pg/ml at admission p Value* No.
Epidemiological data n = 583 n = 257 n = 326
Bio-ADM at admission (pg/ml) 80.5 [41.5–148.0] 36.9 [27.1–51.0] 136.7 [97.6–241.0] < 0.0001
Age (years) 66 [55–76] 64 [53–75] 67 [58–76] 0.0052
Male sex (n, %) 364 (62.4) 171 (66.5) 193 (59.2) 0.0837
Body mass index (kg/m2) 25.7 [22.9–30.1] 25.0 [22.3–28.4] 26.7 [23.2–31.6] 0.0013
Septic shock at admission 293 (50.3) 84 (32.7) 209 (64.1) < 0.0001
Type of ICU admission < 0.0001
Medical 473 (81.1) 230 (89.5) 243 (74.5)
Surgical - emergency procedure 93 (16) 21 (8.2) 72 (22.1)
Surgical - elective procedure 17 (2.9) 6 (2.3) 11 (3.4)
Origin of sepsis < 0.0001
Lung 218 (37.4) 129 (50.2) 89 (27.3)
Bloodstream 90 (15.4) 31 (12.1) 59 (18.1)
Urinary tract 62 (10.6) 10 (3.9) 52 (16)
Catheter 29 (5) 9 (3.5) 20 (6.1)
Peritonitis 31 (5.3) 12 (4.7) 19 (5.8)
Endocarditis 31 (5.3) 12 (4.7) 19 (5.8)
Bile duct infection 8 (1.4) 2 (0.8) 6 (1.8)
CNS 4 (0.7) 4 (1.6) 0 (0)
Skin and soft tissue 10 (1.7) 9 (3.5) 1 (0.3)
Gynecologic 2 (0.3) 1 (0.4) 1 (0.3)
Other 98 (16.8) 38 (14.8) 60 (18.4)
Medical historya
Any cardiac comorbidity 400 (68.6) 147 (57.2) 253 (77.6) < 0.0001
Chronic heart failure 60 (10.3) 19 (7.4) 41 (12.6) 0.0544
Hypertension 293 (50.3) 105 (40.9) 188 (57.7) < 0.0001
Diabetes mellitus 160 (27.4) 57 (22.2) 103 (31.6) 0.0150
Any noncardiac comorbidity 414 (71) 167 (65) 247 (75.8) 0.0058
Chronic renal disease 76 (13.0) 19 (7.4) 57 (17.5) 0.0004
Active/recent malignant tumors 124 (21.3) 34 (13.2) 90 (27.6) < 0.0001
Smoking (active) 117 (20.1) 63 (24.5) 54 (16.6) 0.0302
COPD 89 (15.3) 37 (14.4) 52 (16.0) 0.6421
Any chronic medication 371 (63.6) 138 (53.7) 233 (71.5) < 0.0001
Immunosuppressive therapy 46 (7.9) 11 (4.3) 35 (10.7) 0.0066
Physiological values at admission
Temperature (°C) 37.2 [36.4–38.2] 37.4 [36.6–38.2] 37.1 [36.2–38.1] 0.0034
Mean blood pressure (mmHg) 75 [64–90] 81 [69–95] 72 [60–85] < 0.0001
Heart rate (beats/min) 104 [90–119] 100 [86–116] 105 [94–121] 0.0013
Central venous pressure (mmHg) 8 [5–13] 8 [5–13] 10 [6–14] 0.2419
Glasgow Coma Scale score 15 [14–15] 15 [14–15] 15 [14–15] 0.8161
Fluid balance (ml) 1928 [592–3552] 1425 [500–2699] 2311 [764–4202] < 0.0001
Urine output for 24 h (ml) 1000 [450–1900] 1276 [650–2050] 800 [300–1650] < 0.0001
PaO2/FiO2 228 [137–340] 233.5 [140–360] 223 [137–337] 0.4995
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0.0001). A multivariate model further demonstrated that
bio-ADM had added value on top of APACHE II or
SOFA score (added chi-square 24.4 [p < 0.0001] and 10.2
[p = 0.0014], respectively) (Table 2) when used as a con-
tinuous variable.
With the predefined cutoff value of 70 pg/ml, Kaplan-
Meier analysis confirmed predictive value of bio-ADM
for 28-day mortality in all studied patients (Additional
file 1: Figure S1) and in subgroups of sepsis and septic
shock (Fig. 1a and b). Patient characteristics for high
and low bio-ADM levels are illustrated in Table 1, and
characteristics for survivors versus nonsurvivors are pro-
vided in Additional file 2: Table S1. The optimal Youden
cutoff in all patients was 101.9 pg/ml (sensitivity 67.7%,
specificity 67.3%). In septic shock, the optimal Youden
cutoff was 99.1 pg/ml (sensitivity 71.3%, specificity 52.3%),
and in severe sepsis it was 101.9 pg/ml (sensitivity 57.6%,
specificity 78.6%). This compares with a sensitivity of
77.2% and specificity of 48.9% in all patients for the prede-
fined bio-ADM cutoff of 70 pg/ml.
We additionally assessed outcome in relation to
bio-ADM changes in the initial 48 h in time-dependent
Table 1 Patient characteristics (Continued)
Patient characteristics All Bio-ADM< 70 pg/ml
at admission
Bio-ADM> 70 pg/ml at admission p Value* No.
Laboratory values at admission
Lactate (mmol/L) 1.4 [1.0–2.2] 1.1 [0.8–1.6] 1.8 [1.2–2.7] < 0.0001 n = 562
Arterial pH 7.38 [7.3–7.44] 7.42 [7.36–7.46] 7.36 [7.27–7.42] < 0.0001
Bilirubin (μmol/L) 11 [6–19] 10 [6.5–17] 12 [6–21] 0.1360
Platelets (109/L) 190 [121–275] 196 [136–279] 181 [104–271] 0.0583
Creatinine (mg/dl) 1.4 [0.9–2.2] 1 [0.7–1.4] 1.8 [1.2–2.9] < 0.0001
BUN or urea (mg/dl) 61 [37–107] 44 [28–69] 80 [50–127] < 0.0001
Hematocrit (%) 34 [29–38] 35 [30–38] 34 [29–38] 0.1010
White blood cell count (per mm3) 12,525 [7200–18,585] 13,000 [8475–18,075] 12,025 [5942–19,025] 0.0547
Troponin T, maximum on day 1 42 [18–158] 29 [14–124] 55 [25–176] 0.0230 n = 153
Troponin I, maximum on day 1 69 [20–246] 40 [11–228] 99 [40–289] 0.0049 n = 186
PCT, maximum on day 1 (ng/ml) 11.4 [1.9–49.8] 3.9 [0.9–19.5] 24 [6–84] < 0.0001 n = 330
PCT, central laboratory (ng/ml) 10.2 [2.3–34.3] 3.7 [0.8–13.0] 18.2 [6.0–52.7] < 0.0001 n = 583
BNP, maximum on day 1 257 [102–723] 187 [61–388] 473 [147–1154] 0.0004 n = 131
NT-proBNP, maximum on day 1 4382 [1525–11,565] 2170 [497–6633] 6116 [2816–15,431] 0.0001 n = 117
Organ support at admission
Mechanical ventilation 0.0739
Invasive 219 (37.6) 85 (33.1) 134 (41.1)
Noninvasive 131 (22.5) 67 (26.1) 64 (19.6)
None 233 (40.0) 105 (40.9) 128 (39.3)
Renal replacement therapy 49 (8.4) 8 (3.1) 41 (12.6) 0.0001
Vasopressors/inotropes at admission 349 (59.9) 109 (42.4) 240 (73.6) < 0.0001
Organ dysfunction scores
SOFA (points) 7 [5–10] 5 [3–8] 8 [6–11] < 0.0001 n = 509
APACHE II (points) 15 [11–20] 14 [9–17] 18 [13–22] < 0.0001
Length of stay (days)
ICU 5 [2–10] 4 [2–8] 5 [2–10] 0.0554
Mortality
28-day, deaths (%) 127 (21.8) 30 (11.7) 97 (29.8) < 0.0001
90-day, deaths (%) 166 (28.5) 41 (16) 125 (38.3) < 0.0001
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, bio-ADM Bioactive adrenomedullin, BNP Brain-derived natriuretic peptide, BUN Blood urea
nitrogen, CNS Central nervous system, COPD Chronic obstructive pulmonary disease, ICU Intensive care unit, NT-proBNP N-terminal brain natriuretic peptide, PaO2/
FiO2 Ratio of partial pressure of arterial oxygen to fraction of inspired oxygen, PCT Procalcitonin, SOFA Sequential Organ Failure Assessment
* p Value from nonparametric Kruskal-Wallis or chi-square test, respectively
a Most common comorbidities reported individually
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Cox regression. Bio-ADM trajectory over the initial 48 h
after study inclusion improved prediction of 28-day
survival in the overall population (added chi-square 25.8,
p < 0.0001) (Table 2; Fig. 2, Additional file 3: Figure S2)
and was independent of time-dependent lactate or SOFA
score evaluation (Table 2). Patients were divided into
four groups based on baseline and day 2 bio-ADM
concentrations and under implementation of the cutoff
value of 70 pg/ml: remaining low (low-low, LL), high-to-
low (HL), low-to-high (LH), and remaining high (high-high,
HH). Patient characteristics of these subgroups are pre-
sented in Additional file 4: Table S2.
In patients admitted with high bio-ADM upon admis-
sion, those who decreased bio-ADM towards normal
values within the first 48 h (HL group) had a similar
28-day mortality to the LL group (HL 9.5%, LL 10.5%)
and a more favorable outcome than patients whose bio-
ADM remained high (HH group) or became high
(LH group) (28-day mortality of 38.1% and 38.2%)
(Additional file 4: Table S2).
Bio-ADM levels and organ dysfunction
Bio-ADM levels upon admission correlated with the ini-
tial SOFA score in all studied patients (n = 509, r = 0.49,
p < 0.0001) (Additional file 5: Figure S3). SOFA score
was higher in patients in septic shock than in those in
sepsis, and for each group in patients with high initial
bio-ADM (Additional file 6: Figure S4). Figure 3a indi-
cates that the initial level of circulating bio-ADM relates
to the need for and duration of organ support in survi-
vors (p < 0.0001).
Concerning circulating bio-ADM levels and cardiovas-
cular function, we found an almost linear relationship of
bio-ADM and both cardiovascular SOFA subscore (p <
Table 2 Association between bio-ADM and 28-day mortality
Variables Chi-square added chi-square p Value (added value) Std. HR bio-ADM p Value
bio-ADM (univariate) 54.8 2.3 [1.9–2.9] < 0.0001
Adjusted for SOFA at admission 85.1 10.2 0.0014 1.6 [1.2–2.1] 0.0014
Adjusted for APACHE II at admission 88.9 24.4 < 0.0001 1.9 [1.5–2.4] < 0.0001
Adjusted for covariates 132.1 12.2 0.0005 1.6 [1.1–2.5] 0.0004
bio-ADM (time-dependent Cox) 80.6 25.8 < 0.0001 2.5 [2.1–3.1] < 0.0001
Adjusted for SOFA at admission 89.3 11.5 0.0007 1.8 [1.4–2.2] < 0.0001
Adjusted for APACHE II at admission 108.4 19.5 < 0.0001 2.1 [1.7–2.6] < 0.0001
Adjusted for SOFA (t-d*) 101.0 7.9 0.0049 1.5 [1.1–2.0] 0.0048
Adjusted for lactate (t-d*) 138.0 35.7 < 0.0001 1.9 [1.5–2.3] < 0.0001
APACHE Acute Physiology and Chronic Health Evaluation II, bio-ADM Bioactive adrenomedullin, SOFA Sequential Organ Failure Assessment
Results are from uni- (chi-square), multi- (added chi-square), and *time-dependent Cox regression analysis. *Time-dependent analysis includes measurements
observed at baseline and day 2. n = 562 for covariates (i.e., age, gender, comorbidities [cardiac and noncardiac], diagnosis [sepsis, septic shock], lactate) model due
to missing data for time-dependent lactate, and n = 509 for models including *time-dependent SOFA score
Fig. 1 Twenty-eight-day Kaplan-Meier survival curves of low versus high biologically active adrenomedullin at admission, based on a cutoff value
of 70 pg/ml, in (a) sepsis, and (b) septic shock patients
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0.001) (Additional file 7: Figure S5) and duration of car-
diovascular drug support (Fig. 3b) (p < 0.0001). Under-
standably, patients with high bio-ADM needed
norepinephrine at admission more frequently (73% ver-
sus 42%, p < 0.0001) and at greater dose (0.4 [0.3–0.8]
versus 0.2 [0.1–0.4] μg/kg/min, p = 0.0022) than patients
with low bio-ADM (Additional file 8: Table S3). Our
analysis further revealed that patients with high bio-
ADM at admission needed more vasopressors/inotropes
over the following 7 days even if they did not have those
treatments at admission (Fig. 3c).
Regarding other organ support, patients who needed
volume resuscitation of more than 5 L over the first 2
days (Fig. 3d) (p < 0.0001) or RRT (Additional file 9:
Figure S6) or had long ICU stay (Additional file 10:
Figure S7) had much higher circulating bio-ADM levels
upon ICU admission than those patients who did not.
In agreement with the fact that serial measurements of
bio-ADM indicated survival benefit in patients who
dropped bio-ADM levels at day 2, we could demonstrate
that drop of bio-ADM over the first 2 days also preceded
the decrease of total SOFA score (p value for differences
between HH vs. HL: p < 0.0001 for all days) (Fig. 4).
Finally, using the Sepsis-3 definition of septic shock
(i.e., vasopressor use and lactate ≥ 2mmol/L [or 18 mg/dl]
despite adequate volume resuscitation [17]), our analysis
confirmed that bio-ADM upholds a strong prognostica-
tion for organ recovery and survival in AdrenOSS-1 (both
p < 0.0001) (Additional file 11: Figure S8A and B).
Discussion
The AdrenOSS-1 study was a prospective multinational
observational cohort study assessing the relationship be-
tween rapid changes in circulating bio-ADM levels in
the first 2 days and clinical outcome in ICU patients
with sepsis and septic shock. We confirmed elevated
levels of bio-ADM in septic patients and the striking
relationship between circulating bio-ADM at ICU ad-
mission, organ dysfunction, and death. We also demon-
strated that early recovery of circulating bio-ADM levels
towards normal values (i.e., < 70 pg/ml) was associated
with normalization of vascular function and better
28-day survival.
Our study found moderately elevated circulating levels
of bio-ADM at admission in sepsis and strongly elevated
bio-ADM levels in patients with septic shock, in accord-
ance with earlier reports [13, 14]. Our study also con-
firmed the marked association between bio-ADM level
at admission and short-term mortality as well as the
prognostic cutoff value of 70 pg/ml, previously described
by Marino et al. [14] and Caironi et al. [13] in both sep-
sis and septic shock (including the most recent defin-
ition [17]). Our study showed moderate prognostic value
of bio-ADM at admission using AUC but marked prog-
nostic value using Cox proportional hazards model ad-
justed for various parameters. Moreover, our study
showed that prognostic value of bio-ADM at ICU ad-
mission exerts additive value (positive changes in chi-
square) to various ICU severity scores. We described
also the association between a bio-ADM ≤ 70 pg/ml on
day 2 and very low 28-day mortality, even in patients
with initial high bio-ADM levels. The association of low
bio-ADM by day 2 with full restoration of organ func-
tion at day 7 has been shown as well.
Concerning organ dysfunction, we found a relationship
between circulating bio-ADM at ICU admission and the
subsequent need for cardiovascular and/or renal sup-
port. In our studied patients, high circulating bio-
ADM—known to have vasodilatory actions—might ac-
count for the deterioration of vascular tone and blood
pressure, as previously described [13, 14]. In the present
study, patients with high bio-ADM levels on ICU admis-
sion were more likely to need vasopressors and/or ino-
tropes either at admission or in the following days.
Moreover, they had a higher total fluid balance and
higher incidence of RRT during their ICU stay. The
ADM-induced vascular dysfunction may have contrib-
uted to this condition, although some data suggest that
high bio-AM levels might also be protective to the kid-
ney [19, 20]. Further studies are needed to elucidate the
Fig. 2 Association between the changes of biologically active
adrenomedullin (bio-ADM) levels over 48 h and mortality. HR
between high-high (HH) (levels of bio-ADM remained high) and
high-low (HL) (levels of bio-ADM declining over 48 h) 4.9 (95%
CI 2.5–9.8; HR of LL 1.1 [0.52–2.4]). Only a small number (n = 16,
2.7%; 28-day survival rate 68.8%) of patients who presented with
a low bio-ADM concentration upon admission had higher bio-
ADM level on day 2 (low-high (LH) group), which is why this
group is not represented in the figure
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exact role of bio-ADM in renal function. Of interest, the
relationship between circulating bio-ADM levels and ex-
tent of organ dysfunction, present during ICU admission,
was also true during the recovery phase. Indeed,
bio-ADM levels decreased before the improvement of
total SOFA score in our investigation. Patients with high
bio-ADM levels at ICU admission who showed a decline
towards normal bio-ADM values at day 2 were more likely
to recover vascular function and vasopressor need by day
7. By contrast, the drop in bio-ADM from ICU admission
to day 2 was associated with only limited improvement in
renal function or no improvement in lung function at day
7. These observations also warrant further exploration.
Circulating bio-ADM levels were lower in AdrenOSS-
1 than in the previously described ALBIOS cohort [13].
Indeed, in ALBIOS, septic patients were more severe, as
suggested by greater prevalence of mechanical ventila-
tion, length of stay, and short-term mortality. Likewise,
the prevalence of septic shock was greater in ALBIOS
than in AdrenOSS-1 (Additional file 12: Table S4). Of
note, different definitions of septic shock in the two
studies may have influenced study assessments.
Limitations included that in the present population
only patients with sepsis and septic shock were studied,
and results cannot be directly translated to a general
ICU population. Future studies should focus on extrapo-
lation of our results to patients with hemodynamic in-
stability related to other disease, because as study has
already been performed for cardiogenic shock [21]. Fur-
thermore, our data suggest that ADM may be associated
with myocardial function (e.g., patients with high ADM
also had significantly higher circulating natriuretic
Fig. 3 Association between biologically active adrenomedullin levels upon admission and (a) length of total organ support over the first 7 days
(p < 0.0001), (b) length of vasopressor/inotropic support over the first 7 days (p < 0.0001), (c) overall need for vasopressor support (p < 0.0001), and
(d) total fluid balance over the initial 48 h (p = 0.0001)
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peptide levels). However, data on cardiac function (e.g.,
cardiac output or left ventricular ejection fraction) were
available in only few studied patients. Finally, we used
the cut point of 70 pg/ml of circulating Bio-ADM for
validation of the previously published cut point, even
though the optimal Youden cut points in AdrenOSS-1
showed that 70 pg/ml with respect to a technical opti-
mality criterion is not optimal.
Strong points of the study are the fact that it was a
prospective international multicenter study with a large
number of patients, with a focus on mortality and organ
dysfunction. However, as is true of any observational
study, only associations can be described, and cause-
and-effect relationships cannot be deducted.
Conclusions
In this large prospective international cohort of critic-
ally ill patients admitted to the ICU with sepsis or sep-
tic shock, we confirmed the strict relationship between
high levels of bio-ADM at ICU admission and organ
dysfunction and mortality. We demonstrated that early
decrease towards the normal values of circulating
bio-ADM in the first days after ICU admission was associ-
ated with improvement of cardiovascular and renal func-
tion and was associated with very low 28-day mortality.
Appendix
Collaborators
Belgium, Brussels: Pierre-François Laterre, Caroline
Berghe, Marie-France Dujardin, Suzanne Renard, Xavier
Wittebole, Christine Collienne, Diego Castanares
Zapatero; Ottignies: Thierry Dugernier, Marco Vinetti,
Nicolas De Schryver, Anne Thirifays, Jacques Mairesse;
Haine-St-Paul: Vincent Huberlant, Hélène Petre, Isabelle
Buelens, Pierre Henin, Hugues Trine, Yves Laurent, Loix
Sébastien, Paul Geukens, Laurent Kehl. France, Limoges:
Bruno François, Philippe Vignon, Nicolas Pichon,
Emmanuelle Begot, Anne-Laure Fedou, Catherine
Chapellas, Antoine Galy, Nicolas Rodier, Ludmilla
Baudrillart, Michelle Nouaille, Séverine Laleu, Claire
Mancia, Thomas Daix, Paul Bourzeix, Isabelle Herafa,
Anne-Aurore Duchambon; La Roche sur Yon: Jean
Baptiste Lascarrou, Maud Fiancette, Gwenhael Colin,
Matthieu Henry-Lagarrigue, Jean-Claude Lacherade,
Christine Lebert, Laurent Martin-Levèvre, Isabelle
Vinatier, Aihem Yehia, Konstantinos Bachoumas, Aurélie
Joret, Jean Reignier, Cécille Rousseau, Natacha
Maquigneau, Yolaine Alcourt, Vanessa Erragne
Zinzonni, Angélique Deschamps, Angelina Robert;
Tours: Emmanuelle Mercier, Véronique Simeon-
Vieules, Aurélie Aubrey, Christine Mabilat, Denis
Garot, Stephan Ehrmann, Annick Legras, Manikikian,
Youenn Jouan, Pierre-François Dequin, Antoine Guillon,
Laetitia Bodet-Contentin, Emmannuelle Rouve, Charlotte
Salmon, Lysiane Brick, Stéphanie Massat; Angoulême:
Arnaud Desachy, Marie Anne Fally, Laurence Robin,
Christophe Cracco, Charles Lafon, Sylvie Calvat, Stéphane
Rouleau, David Schnell; Angers: Sigismond Lasocki,
Philippe Fesard, Damien Leblanc, Guillaume Bouhours,
Claire Chassier, Mathieu Conte, Thomas Gaillard, Floriane
Denou, Mathieu Kerymel, Marion Guyon, Anthéa Loiez,
Stéphanie Lebreton; Strasbourg – Nouvel Hôpital Civil:
Ferhat Meziani, Hayat Allam, Samir Chenaf, Hassène
Rahmani, Sarah Heenen, Christine Kummerlen, Xavier
Fig. 4 The absolute Sequential Organ Failure Assessment (SOFA) scores at (a) admission, (b) day 2, and (c) day 7 for groups high-high (HH; i.e., above
70 pg/ml at baseline and day 2), high-low (HL), and low-low (LL), excluding patients who died within 7 days. p Value for differences between HH vs.
LL: p < 0.0001 for all days; p value for HH vs. HL: p < 0.0001 for all days; p Values for HL vs. LL: p < 0.0001, 0.6016, and 0.9969 for days 1, 3, and 7,
respectively. Of note, the number of patients is less at day 2 than at day 7 because there were more values missing at day 2 owing to the fact that
discharged patients (mostly at day 7) were given a SOFA score of 0. Furthermore, only a small number (n = 16, 2.7%) of patients who presented with a
low bio-ADM concentration upon admission had a higher bio-ADM level on day 2 (low-high [LH] group), which is why this group is not represented
in the figure. Median (IQR) SOFA scores for the LH group were 7.5 (6.0–9.8), 9.0 (4.0–11.2), and 4.0 (0.0–6.5) for admission, day 2, and day 7, respectively
Mebazaa et al. Critical Care          (2018) 22:354 Page 9 of 12
Delabranche, Alexandra Boivin, Raphaël Clere-Jehl,
Yannick Rabouël; Strasbourg – Hôpital HautePierre: Julien
Pottecher, Sophie Bayer, Catherine Metzger, Stéphane
Hecketsweiler, Pierre Olivier Ludes, Hortense Besancenot,
Nadia Dhif, Guy Freys, Jean-Marc Lessinger, Anne
Launoy, Aude Ruimy, Alain Meyer, M Szozot; Paris –
Hôpital Lariboisière: Alexandre Mebazaa, Nicolas Deye,
Etienne Gayat, Marie-Céline Fournier, Sarra Abroug, Badr
Louadah, Elodie Feliot, Sebastian Voicu, Malissin I, Bruno
Megarbane, Philippe Manivet, Gardianot Victori, DaSilva
Kelly, Béatrice Foucher, Valérie Pierre, Lamia Kerdjana,
Thomas Beeken, Antoine Goury, Pierre Garcon, Samuel
Gaugain, Benjamin Glen Chousterman, Benjamin Huot,
Romain Barthelemy, Benjamin Soyer; Paris – Hôpital St
Louis: Laurent Jacob, Matthieu Legrand, Marie-Céline
Fournier, Francine Bonnet, Chloé Legall, Haikel Oueslati,
Alexandru Cupaciu, Philippe Manivet, Badr Louadah;
Paris – Hôpital Bichat: Romain Sonneville, Sophie Letrou,
Lila Bouadma, Bruno Mourvillier, Véronique Deiler, Eric
Magalhaes, Mathilde Neuville, Jean-François Timsit,
Aguila Radjou; Colombes: Stéphane Gaudry, Emeline
Dubief, Jonathan Messika, Béatrice La Combe, Damien
Roux, Guillaume Berquier, Mohamed Laissi, Jean-Damien
Ricard; Clermont Ferrand: Jean-Michel Constantin,
Sebastien Perbet, Julie Delmas, Julien Pascal, Sophie
Cayot, Renaud Guerin, Matthieu Jabaudon, Laurence
Roszyk, Christine Rolhion, Justine Bourdier, Mathilde
Lematte, Charlène Gouhier, Camille Verlhac, Thomas
Godet, Sophiano Radji, Elodie Caumon, Sandrine
Thibault. Germany, Aachen: Nikolaus Marx, Tobias
Schuerholz, Jessica Pezechk, Florian Feld, Christian Brülls,
Thorben Beeker, Tim-Philipp Simon, Robert Deisz, Achim
Schindler, Bianca Meier, Thorsten Janisch; Köln: Andreas
Hohn, Dirk Schedler, Wolfgang Wetsch, Daniel Schröder;
Erfurt: Andreas Meier-Hellmann, Alexander Lucht,
Robert Henker, Magdalena Römmer, Torsten Meinig;
Frankfurt: Kai D. Zacharowski, Patrick Meybohm, Simone
Lindau, Haitham Mutlak; Hamburg: Stefan Kluge, Grit
Ringeis, Birgit Füllekrug, Brigitte Singer, Axel Nierhaus,
Katrin Bangert, Geraldine de Heer, Daniel Frings, Valentin
Fuhrmann, Jakob Müller, Jörg Schreiber, Barbara Sensen,
Stephanie Siedler, Annekatrin Siewecke, Gerold Söffker,
Dominic Wichmann, Mélanie Kerinn; Augsburg: Ulrich
Jaschinski, Ilse Kreuser, Marlene Zanquila; Jena: Andreas
Kortgen, Frank Bloos, Falk Gonnert, Daniel Thomas-
Rüddel, Anja Haucke, Steffi Kolanos, Karina Knuhr
Kohlberg, Petra Bloos, Katrin Schwope. Italy, Rome:
Sant’Andrea Hospital: Salvatore Di Somma, Marino
Rossella, Veronica Russo, Santarelli Simona, Christopher
Bartoli, Sylvia Navarin, Cristina Bongiovanni, Michela
Orru, Daniela Quatrocchi, Giada Zoccoli, Antonella
Varchetta; Rome – Policlinico Universitario A. Gemelli:
Massimo Antonelli, Gennaro de Pascale, Maria Sole
Vallecoccia, Salvatore Lucio Cutuli, Valentina Digravio,
Daniela Quattrochi, Sonia D’Arrigo, Filippo Elvino Leone.
The Netherlands, Enschede: Bert Beishuizen, Martin
Rinket, Natalie Border, Mariska Bos-Burgmeijer, Astrid
Braad, S Papendorp, Alexander Cornet, J Vermeijden,
Ronald J Trof; Nijmegen: Peter Pickkers, Marieke van de
A, Helen Van Wezel, Leo Heunks, Natalie Border, Chantal
Luijten-Arts, Astrid Hoedemaekers, Hans van der Hoeven,
Noortje Roovers, Pleun Hemelaar.
Annex: Sponsoring
sphingotec GmbH
Neuendorfstraße 15a
16761 Hennigsdorf
Germany
Annex: Management
European Drug Development Hub (EDDH),
Vandoeuvres Les Nancy: Stéphanie Grojean, Laetitia
Tourneur, Virginie Barthel
Additional files
Additional file 1: Figure S1. Twenty-eight-day Kaplan-Meier survival
curves of low versus high bio-ADM at admission (bioADM.d0) in all
patients, based on a cutoff value of 70 pg/ml. (TIF 207 kb)
Additional file 2: Table S1. Patient characteristics of survivors and
nonsurvivors. (DOCX 50 kb)
Additional file 3: Figure S2. Bio-ADM levels at baseline and on day
2 in 28-day survivors and nonsurvivors. If data were missing at day 2
(e.g., owing to death or discharge; 12.7%), the last available measure-
ment was carried forward. Horizontal lines at 70 and 130 pg/ml for
better orientation; y-axis is truncated at 300 pg/ml. (TIF 206 kb)
Additional file 4: Table S2. Patient characteristics of the four different
groups with respect to adrenomedullin trajectory over the first 48 h after
study inclusion. (DOCX 56 kb)
Additional file 5: Figure S3. Association between the initial bio-ADM
concentration and initial SOFA score (r = 0.49, n = 509, p < 0.0001; missing
values due to missing SOFA score components). (TIF 199 kb)
Additional file 6: Figure S4. Association of initial SOFA score by sepsis
and septic shock and initial bio-ADM concentration below or above 70 pg/
ml (p < 0.0001 for both bio-ADM and diagnosis; p = 0.2015 for interaction;
two-way analysis of variance). All data are from admission. (TIF 195 kb)
Additional file 7: Figure S5. Relationship between bio-ADM and
cardiovascular SOFA subscore (p < 0.001). (JPG 25 kb)
Additional file 8: Table S3. Association between adrenomedullin and
need of vasopressors/inotropes at admission. (DOCX 23 kb)
Additional file 9: Figure S6. Association between bio-ADM concen-
tration on admission and need for renal replacement therapy on
admission, later during ICU stay, or never (70.4 [36.3–128.8] vs. 149.0
[87.1–320.5] and 162.6 [99.8–367.3] pg/ml, for patients without need
for RRT, on admission, or later during ICU stay, respectively,
p < 0.0001). (TIF 221 kb)
Additional file 10: Figure S7. Bio-ADM levels upon admission in
28-day survivors and time to ICU discharge (p < 0.0001): Patients with
early discharge (< 2 days) are significantly different from all other groups
(all p < 0.016), and late discharge (> 21 days) is significantly different from
early discharge (< 2 days and 2–7 days, both p < 0.013). (TIF 217 kb)
Additional file 11: Figure S8. Twenty-eight-day Kaplan-Meier survival
curves of low versus high bio-ADM at admission, based on a cutoff value of
70 pg/ml, in patients with lactate > 2 mmol/L (p < 0.0001) (a) and SOFA
score (b) for low versus high bio-ADM at admission (p < 0.0001). (TIF 229 kb)
Additional file 12: Table S4. Comparison of AdrenOSS-1 and ALBIOS.
(DOCX 24 kb)
Mebazaa et al. Critical Care          (2018) 22:354 Page 10 of 12
Abbreviations
ADM: Adrenomedullin; AdrenOSS: Adrenomedullin and Outcome in Sepsis
and Septic Shock; APACHE II: Acute Physiologic Assessment and Chronic
Health Evaluation II; bio-ADM: Biologically active adrenomedullin; BNP: Brain-
derived natriuretic peptide; BUN: Blood urea nitrogen; CNS: Central
nervous system; COPD: Chronic obstructive pulmonary disease;
ICU: Intensive care unit; NT-proBNP: N-terminal brain natriuretic peptide;
PaO2/FiO2: Ratio of partial pressure of arterial oxygen to fraction of
inspired oxygen; PCT: Procalcitonin; RRT: Renal replacement therapy;
SOFA: Sequential Organ Failure Assessment
Acknowledgements
The authors are particularly grateful to Marie-Céline Fournier, who coordi-
nated organizational aspects of the study. The authors also thank the Centre
de Recherche Clinique (CRC) of Lariboisière University Hospital for support.
Listing of site investigators of the AdrenOSS-1 study
Centers Name
Cliniques Universitaires Saint-Luc, Brussels, Belgium Laterre
Clinique St Pierre, Ottignies, Belgium Dugernier
Hôpital Jolimont, Haine-St-Paul, Belgium Huberlant
Klinik für Operative Intensivmedizin und Intermediate Care,
Universitätsklinikum der RWTH, Aachen, Germany
Marx
Klinik für Anästhesiologie und Operative Intensivmedizin,
Universitätsklinikum Köln, Köln, Germany
Hohn
HELIOS-Klinikum Erfurt, Erfurt, Germany Meier-Hellmann
Klinikum Augsburg, Augsburg, Germany Jaschinski
Klinik für Anästhesiologie und Intensivmedizin,
Jena, Germany
Kortgen
CHU Dupuytren, Limoges, France Francois
CHD les Oudairies, La Roche sur Yon, France Lascarrou
CHU de Tours, Tours, France Mercier
Centre hospitalier d’Angoulême, Angoulême, France Desachy
CHU Angers, Angers, France Lasocki
Hôpital Lariboisière, Paris, France (two centers) Mebazaa
Hôpital Saint-Louis 1, Paris, France Jacob
Hôpital Louis Mourier, Colombes, France Gaudry
Hôpital Hautepierre, Strasbourg, France Pottecher
CHU Estaing, Clermont Ferrand, France Constantin
Hôpital Bichat Claude-Bernard, Paris, France Sonneville
Sant’Andrea Hospital, Rome, Italy Disomma
Policlinico Universitario A. Gemelli, Rome, Italy Antonelli
Medisch Spectrum Twente, Enschede, The Netherlands Beishuizen
UMC Radboudziekenhuis, Nijmegen, The Netherlands Pickkers
Funding
AdrenOSS-1 (ClinicalTrials.gov identifier NCT02393781) was funded by
sphingotec GmbH, Neuendorfstraße 15a, 16761 Hennigsdorf, Germany.
This project has received funding from the European Union’s Horizon
2020 research and innovation program under grant agreement 666328.
Availability of data and materials
AM and PFL had full access to all data in the study and take responsibility for
the integrity of the data and the accuracy of the data analysis.
Authors’ contributions
AB, OH, PFL, AM, PS, and JS conceived of and designed the study. All
collaborators acquired data (see Appendix). AB, CG, AH, AM, PFL, and JS
analyzed and interpreted data. CG, AH, and AM drafted the manuscript. All
authors critically revised the manuscript for important intellectual content.
OH performed statistical analysis. PFL, AM, and sphingotec obtained funding.
sphingotec provided administrative, technical, or material support. PFL, AM,
and sphingotec supervised the study. All authors read and approved the
final manuscript.
Authors’ information
Sponsor
sphingotec GmbH
Neuendorfstraße 15a
16761 Hennigsdorf
Germany
Principal investigators
Prof. Dr. Alexandre Mebazaa, Head
Department of Anesthesiology and Critical Care Medicine
AP-HP, Saint Louis and Lariboisière University Hospitals
Paris, France
Tel: + 33 1 49 95 80 83
Fax: + 33 1 49 95 80 71
Prof. Pierre-François Laterre, Head of Clinical Service
Saint Luc University Hospital at the Université Catholique de Louvain
Brussels, Belgium
Tel: + 32 2764 27 35
Fax: + 32 2764 89 28
Ethics approval and consent to participate
The present study was conducted in France, Belgium, The Netherlands, Italy,
and Germany. The study protocol was approved by the local ethics
committees, and the study was conducted in accordance with Directive
2001/20/EC as well as good clinical practice (International Conference on
Harmonization Harmonized Tripartite Guideline version 4 of May 1, 1996, and
decision of November 24, 2006) and the Declaration of Helsinki. Patients
were included from June 2015 to May 2016.
Consent for publication
Not applicable.
Competing interests
AM has received speaker’s honoraria from Novartis, Orion, and Servier and
fees as a member of the advisory board and/or steering committee from
Cardiorentis, Adrenomed, sphingotec, Sanofi, Roche, Abbott, and Bristol-
Myers Squibb. EG has received consulting fees from Adrenomed, Roche
Diagnostics, and Magnisense and lecture fees from Edwards Lifesciences. AB
is the managing director of sphingotec GmbH and holds shares in it. OH
and JS are employees of sphingotec GmbH, the company that developed
and holds patent rights in the bio-ADM assay. BF has received consulting
fees from Aridis, Ferring, Arsanis, Inotrem, and Lascco. PP serves as a consult-
ant for and has received consulting fees from Adrenomed. The other authors
report no conflicts of interest. ML has received lecture fees from Alere, Frese-
nius, and Gilead Sciences and consulting fees from Adrenomed. PFL has re-
ceived consulting fees from Adrenomed, Ferring, and Lascco. The other
authors report no conflicts of interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Anesthesiology, Burn and Critical Care Medicine, AP-HP,
Saint Louis and Lariboisière University Hospitals, 2 rue A. Paré, 75010 Paris,
France. 2Inserm 942, Paris, France. 3University Paris Diderot, Paris, France.
4Department of Intensive Care Medicine, Radboud University Medical Center,
Geert Grooteplein Zuid 10, 6500, HB, Nijmegen, The Netherlands.
5Department of Anesthesia, Surgical Intensive Care, Prehospital Emergency
Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland.
6Department of Critical Care Medicine, St Luc University Hospital, Université
Catholique de Louvain, Brussels, Belgium. 7sphingotec GmbH, Hennigsdorf,
Mebazaa et al. Critical Care          (2018) 22:354 Page 11 of 12
Germany. 8Adrenomed AG, Hennigsdorf, Germany. 9Fondazione Policlinico
Universitario A. Gemelli, Rome, Italy. 10Department of Intensive Care,
Medische Spectrum Twente, Enschede, The Netherlands. 11Department of
Perioperative Medicine, University Hospital of Clermont-Ferrand,
Clermont-Ferrand, France. 12Sant’ Andrea Hospital, Rome, Italy. 13Clinique St
Pierre, Ottignies, Belgium. 14ICU Department, CHU Dupuytren, Limoges,
France. 15INSERM CIC 1435/UMR 1092, Limoges, France. 16Hôpital Louis
Mourier, Colombes, France. 17Hôpital Jolimont, Haine-St-Paul, Belgium.
18Centre Hospitalier Universitaire de Nantes, Nantes, France. 19Klinik für
Operative Intensivmedizin und Intermediate Care, Universitätsklinikum der
RWTH, Aachen, Germany. 20CHU de Tours, Tours, France. 21Hopital Bichat
Claude-Bernard, Paris, France. 22Department of Critical Care Medicine, Saint
Luc University Hospital, Université Catholique de Louvain, Avenue Hippocrate
10, 1200 Brussels, Belgium.
Received: 25 March 2018 Accepted: 16 October 2018
References
1. Kox M, Pickkers P: Adrenomedullin: its double-edged sword during sepsis
slices yet again. Intensive Care Med Exp. 2014;2(1):1.
2. Nuki C, Kawasaki H, Kitamura K, Takenaga M, Kangawa K, Eto T, Wada A.
Vasodilator effect of adrenomedullin and calcitonin gene-related peptide
receptors in rat mesenteric vascular beds. Biochem Biophys Res Commun.
1993;196(1):245–51.
3. Passaglia P, Gonzaga NA, Tirapelli DP, Tirapelli LF, Tirapelli CR.
Pharmacological characterisation of the mechanisms underlying the
relaxant effect of adrenomedullin in the rat carotid artery. J Pharm
Pharmacol. 2014;66(12):1734–46.
4. Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K. Potent
and long-lasting vasodilatory effects of adrenomedullin in humans:
comparisons between normal subjects and patients with chronic heart
failure. Circulation. 1997;95(5):1214–21.
5. Hippenstiel S, Witzenrath M, Schmeck B, Hocke A, Krisp M, Krüll M, Seybold
J, Seeger W, Rascher W, Schütte H, et al. Adrenomedullin reduces
endothelial hyperpermeability. Circ Res. 2002;91:618–25.
6. Brell B, Temmesfeld-Wollbruck B, Altzschner I, Frisch E, Schmeck B, Hocke
AC, Suttorp N, Hippenstiel S. Adrenomedullin reduces Staphylococcus aureus
alpha-toxin-induced rat ileum microcirculatory damage. Crit Care Med. 2005;
33(4):819–26.
7. García Ponce A, Citalán Madrid AF, Vargas Robles H, Chánez Paredes S, Nava
P, Betanzos A, Zarbock A, Rottner K, Vestweber D, Schnoor M. Loss of
cortactin causes endothelial barrier dysfunction via disturbed
adrenomedullin secretion and actomyosin contractility. Sci Rep. 2016;
6:29003.
8. Temmesfeld-Wollbruck B, Brell B, David I, Dorenberg M, Adolphs J,
Schmeck B, Suttorp N, Hippenstiel S. Adrenomedullin reduces vascular
hyperpermeability and improves survival in rat septic shock. Intensive
Care Med. 2007;33(4):703–10.
9. Hocke AC, Temmesfeld-Wollbrueck B, Schmeck B, Berger K, Frisch EM,
Witzenrath M, Brell B, Suttorp N, Hippenstiel S. Perturbation of endothelial
junction proteins by Staphylococcus aureus alpha-toxin: inhibition of
endothelial gap formation by adrenomedullin. Histochem Cell Biol. 2006;
126(3):305–16.
10. Muller HC, Witzenrath M, Tschernig T, Gutbier B, Hippenstiel S, Santel A,
Suttorp N, Rosseau S. Adrenomedullin attenuates ventilator-induced lung
injury in mice. Thorax. 2010;65(12):1077–84.
11. Guignant C, Voirin N, Venet F, Poitevin F, Malcus C, Bohe J, Lepape A,
Monneret G. Assessment of pro-vasopressin and pro-adrenomedullin as
predictors of 28-day mortality in septic shock patients. Intensive Care Med.
2009;35(11):1859–67.
12. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B.
Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an
observational study. Crit Care. 2005;9(6):R816–24.
13. Caironi P, Latini R, Struck J, Hartmann O, Bergmann A, Maggio G, Cavana M,
Tognoni G, Pesenti A, Gattinoni L, et al. Circulating biologically active
adrenomedullin (bio-ADM) predicts hemodynamic support requirement and
mortality during sepsis. Chest. 2017;152(2):312–20.
14. Marino R, Struck J, Maisel AS, Magrini L, Bergmann A, Di Somma S. Plasma
adrenomedullin is associated with short-term mortality and vasopressor
requirement in patients admitted with sepsis. Crit Care. 2014;18(1):R34.
15. Geven C, Kox M, Pickkers P. Adrenomedullin and adrenomedullin-targeted
therapy as treatment strategies relevant for sepsis. Front Immunol. 2018;
9:292.
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal
SM, Vincent JL, Ramsay G, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International
Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250–6.
17. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer
M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The Third
International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
JAMA. 2016;315(8):801–10.
18. Weber J, Sachse J, Bergmann S, Sparwaßer A, Struck J, Bergmann A.
Sandwich immunoassay for bioactive plasma adrenomedullin. J Appl Lab
Med. 2017;2(2):222-33. https://doi.org/10.1373/jalm.2017.023655.
19. Inal S, Koc E, Ulusal-Okyay G, Pasaoglu OT, Isik-Gonul I, Oz-Oyar E, Pasaoglu
H, Guz G. Protective effect of adrenomedullin on contrast induced
nephropathy in rats. Nefrologia. 2014;34(6):724–31.
20. Oyar EO, Kiris I, Gulmen S, Ceyhan BM, Cure MC, Delibas N, Lortlar N,
Okutan H. The protective effect of adrenomedullin on renal injury, in a
model of abdominal aorta cross-clamping. Thorac Cardiovasc Surg. 2012;
60(1):5–10.
21. Tolppanen H, Rivas-Lasarte M, Lassus J, Sans-Rosello J, Hartmann O,
Lindholm M, Arrigo M, Tarvasmaki T, Kober L, Thiele H, et al.
Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction,
and poor prognosis in cardiogenic shock. Ann Intensive Care. 2017;7(1):6.
Mebazaa et al. Critical Care          (2018) 22:354 Page 12 of 12
